Anne Jones - Celularity Exec Officer
| CELU Stock | USD 2.04 0.03 1.49% |
Insider
Anne Jones is Exec Officer of Celularity
| Age | 53 |
| Address | 170 Park Avenue, Florham Park, NJ, United States, 07932 |
| Phone | 908 768 2170 |
| Web | https://www.celularity.com |
Anne Jones Latest Insider Activity
Tracking and analyzing the buying and selling activities of Anne Jones against Celularity stock is an integral part of due diligence when investing in Celularity. Anne Jones insider activity provides valuable insight into whether Celularity is net buyers or sellers over its current business cycle. Note, Celularity insiders must abide by specific rules, including filing SEC forms every time they buy or sell Celularity'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Anne Jones over six months ago Disposition of 10624 shares by Anne Jones of MDU Resources at 20.86 subject to Rule 16b-3 | ||
Anne Jones over six months ago Disposition of 10624 shares by Anne Jones of MDU Resources at 20.86 subject to Rule 16b-3 |
Celularity Management Efficiency
The company has return on total asset (ROA) of (0.1463) % which means that it has lost $0.1463 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5423) %, meaning that it created substantial loss on money invested by shareholders. Celularity's management efficiency ratios could be used to measure how well Celularity manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -1.49 in 2024. Return On Capital Employed is likely to gain to -2.39 in 2024. Total Current Liabilities is likely to gain to about 70.7 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 338.4 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Daren Ure | Hepion Pharmaceuticals | N/A | |
| Gabriel BA | Immix Biopharma | 37 | |
| MBA MD | Immix Biopharma | 49 | |
| LaBella MS | ZyVersa Therapeutics | 66 | |
| Todd MD | Hepion Pharmaceuticals | 55 | |
| JD MBA | Immix Biopharma | N/A | |
| Launa Aspeslet | Hepion Pharmaceuticals | N/A | |
| Sharen Pyatetskaya | Hepion Pharmaceuticals | ||
| Karen Cashmere | ZyVersa Therapeutics | 72 | |
| Manuel Dafonseca | Sonnet Biotherapeutics Holdings | N/A | |
| BSc BSc | Hepion Pharmaceuticals | 66 | |
| Stephen MD | Hepion Pharmaceuticals | N/A | |
| Donald Picker | Cns Pharmaceuticals | 78 | |
| Nandan BS | Immix Biopharma | 62 | |
| CPA CTP | Cns Pharmaceuticals | 44 | |
| Susan Dexter | Sonnet Biotherapeutics Holdings | 69 | |
| DSc MSE | Immix Biopharma | 75 | |
| MD FACP | Sonnet Biotherapeutics Holdings | 66 | |
| Pablo MD | ZyVersa Therapeutics | N/A | |
| John Cini | Sonnet Biotherapeutics Holdings | 71 | |
| Waldemar Priebe | Cns Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -1.54 | ||||
| Return On Asset | -0.15 |
Celularity Leadership Team
Elected by the shareholders, the Celularity's board of directors comprises two types of representatives: Celularity inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Celularity. The board's role is to monitor Celularity's management team and ensure that shareholders' interests are well served. Celularity's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Celularity's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Carlos Ramirez, SVP Relations | ||
| Sharmila MD, Senior Safety | ||
| CFA CFA, Chief Officer | ||
| Tim Wilk, Senior Operations | ||
| Ramji Krishnan, Chief Officer | ||
| Bradley Glover, Ex COO | ||
| CPA MS, Treasurer | ||
| Stephen DPM, President Diseases | ||
| David CFA, Chief Officer | ||
| MBA MD, Chief VP | ||
| John Haines, Global EVP | ||
| Robert MD, CEO Founder | ||
| Beth Steinbrenner, Ex HR | ||
| Timothy Smith, Secretary | ||
| Keary Esq, Gen EVP | ||
| Anne Jones, Exec Officer | ||
| Kyle Esq, General VP |
Celularity Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Celularity a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.54 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (2.64) % | ||||
| Operating Margin | (0.84) % | ||||
| Current Valuation | 111.78 M | ||||
| Shares Outstanding | 22.01 M | ||||
| Shares Owned By Insiders | 50.39 % | ||||
| Shares Owned By Institutions | 14.84 % | ||||
| Number Of Shares Shorted | 934.46 K | ||||
| Price To Earning | 3.08 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Celularity Stock Analysis
When running Celularity's price analysis, check to measure Celularity's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celularity is operating at the current time. Most of Celularity's value examination focuses on studying past and present price action to predict the probability of Celularity's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celularity's price. Additionally, you may evaluate how the addition of Celularity to your portfolios can decrease your overall portfolio volatility.